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Abstract
Purpose The classical consequence of vitamin D defi-
ciency is osteomalacia, but recent insights into the function
of vitamin D suggest that it may play a role in other body
systems as well. The objective of this study was to examine
the association between 25-hydroxyvitamin D (25(OH)D)
and markers of glucose metabolism (n = 593), global
cognitive functioning (n = 116) and depression (n = 118)
in European elderly participating in the SENECA study.
Moreover, we wanted to explore whether the observed
associations of 25(OH)D with depression and global cog-
nitive performance were mediated by fasting plasma glu-
cose (FPG) levels.
Methods Cross-sectional associations between 25(OH)D
and FPG, fasting plasma insulin (FPI) and homeostatic
model assessment-insulin resistance (HOMA-IR), a marker
of insulin resistance, were estimated from multiple
regression analyses. Associations of 25(OH)D with global
cognitive functioning (Mini Mental State Examination) and
depression (Geriatric Depression Scale) were examined
using Poisson regression.
Results An inverse association was observed between
25(OH)D and FPG (b-0.001), indicating a 1 % decrease in
FPG per 10 nmol/L increase in 25(OH)D, but after full
adjustment for demographic factors, lifestyle factors and
calcium intake, this association was not statistically sig-
nificant (P = 0.07). Although participants with intermedi-
ate and high serum 25(OH)D levels showed a tendency
towards a lower depression score after adjustment for
demographic and lifestyle factors, RR and 95 % CI: 0.73
(0.51–1.04) and 0.76 (0.52–1.11), respectively, these find-
ings were not statistically significant.
Conclusion An inverse association of 25(OH)D with
depression and FPG was observed, but this association was
not statistically significant. There was no association
between 25(OH)D with FPI and HOMA-IR or with global
cognitive functioning. More studies are needed to further
explore the possible role of vitamin D in the various body
systems.
Keywords Vitamin D  Type 2 diabetes mellitus  Insulin
sensitivity  Dementia  Depression  Cross-sectional
Introduction
Worldwide, approximately 347 million people are affected
by diabetes [1], mainly type 2 diabetes. Recent epidemio-
logical studies suggest that diabetic patients are at
increased risk of dementia [2] and depression [3]. The
question whether the observed associations between these
three ageing-related diseases are the result of shared risk
factors or specific biological mechanisms, however,
remains to be solved. Vitamin D deficiency is one of the
postulated links [4–8].
Hypovitaminosis D is commonly observed in the elderly
population. A restricted ultraviolet light exposure, low
vitamin D intake and a decreased skin synthesis capacity
may be related to the development of vitamin D deficiency
in ageing populations. In NHANES III, Martins and col-
leagues observed lower 25(OH)D levels in women, persons
C60 years and obese and diabetic participants [9]. In 1984,
a study among middle-aged and elderly English men and
women showed that post-prandial glucose levels were
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highest during the winter period [10]. Since then, evi-
dence supporting a role for vitamin D in glucose metab-
olism expanded, including among others the identification
of vitamin D receptors in the human pancreatic b-cell
[11], the expression of 1-a-hydroxylase enzyme in the
b-cell [12] and stimulation of the expression of insulin
receptors by vitamin D in vitro [13]. The presence of 1-a-
hydroxylase in cerebrospinal fluid and the existence of
vitamin D receptors (VDRs) on various brain structures
[14] support the hypothesis that vitamin D is involved in
mental health.
However, while animal experiments point towards a
protective effect of vitamin D with regard to the develop-
ment of several age-related diseases, population-based
studies have not yet provided conclusive evidence for the
association with diabetes [4, 15], cognitive functioning
[16–24] and depression [6–8, 25–28]. Therefore, our
objective in this European multicentre cohort study was to
examine 25(OH)D and the association with markers of
glucose metabolism, cognitive functioning and depression
in elderly men and women.
Methods
Subjects
The study is conducted using baseline data collected from
European elderly participating in the SENECA study;
Survey in Europe on Nutrition and the Elderly, a Concerted
Action [29]. Men and women aged 70–75 years who were
living in pre selected towns across Europe were invited for
participation in the study. Towns were selected based upon
their representativeness of the population and socio-eco-
nomic structure for the whole country. Psycho-geriatric
patients living in nursing homes, persons who were not
fluent in the country’s language or not able to indepen-
dently answer questions were excluded from participation.
The total SENECA population comprised 2,586 partici-
pants. Markers of glucose metabolism and serum 25(OH)D
levels were measured in 1989 and available for 1,554 and
860 participants, respectively. Of 593 participants, both
25(OH)D and markers of glucose metabolism were mea-
sured. Data on cognitive functioning and depression were
obtained in 1993 and available for 443 and 482 partici-
pants, of whom serum 25(OH)D levels were measured in
116 and 118 participants, respectively. Measurements of
serum 25(OH)D, markers of glucose metabolism and
mental health were available of 98 (GDS) and 94 (MMSE)
participants (Fig. 1). Included in the analyses were partic-
ipants from: Belgium: Hamme; Denmark: Roskilde;
France: Strassbourg and Valence; Hungary: Monor; the
Netherlands: Culemborg; Norway: Elverum; Switzerland:
Yverdon, Burgdorf, and Bellinzona; Greece: Athens and
Iraklion; Portugal: Lisbon; Spain: Madrid.
Mental status
Global cognitive functioning was assessed using the
mini mental state examination (MMSE). The variable for
analyses was defined as the maximum MMSE score minus
the MMSE score of the participant, reflecting the number
of erroneous answers. Mitchell et al. [30] recently reviewed
the accuracy of the MMSE and showed a 85.1 % sensi-
tivity and a 85.5 % specificity in non-clinical community
settings. The 15-item geriatric depression scale (GDS) was
used as a screenings tool for depression. Validation with
the diagnostic and statistical manual of mental disorders
(DSM-IV) revealed that 97.0 % of the persons with
depression (sensitivity) and 54.8 % persons without
depression (specificity) were correctly classified [31].
Biochemical analyses
Blood samples were taken between 7.30 and 9.30 AM
while the participant was in a fasting state. Fasting blood
samples (25 mL) were collected and 10 mL was trans-
ferred to another tube for serum separation. A portion
(0–5 mL) of each serum sample was stored at -80 C for
25(OH)D determination. All blood samples were sent on
dry ice to the coordinating centre in Wageningen, the
Netherlands, and stored at -80 C. Serum 25(OH)D values
were analysed by competitive protein-binding assay
(coefficients of variation: within-assay 4–7 %, between-
assay 7–10 %) at the TNO Nutrition and Food Research
Institute, Zeist, the Netherlands. As 25(OH)D concentra-
tions may fluctuate seasonally, 25(OH)D was only deter-
mined in blood samples collected between January and
March 1989. Plasma glucose concentration was measured
by the hexokinase method using the Hitachi 911 auto-
analyser. Plasma insulin concentration was measured by
using enzyme immunoassay (Boehringer-Mannheim,
Mannheim, Germany), and insulin resistance was calcu-
lated using homeostatic model assessment-insulin resis-
tance (HOMA-IR) from glucose and insulin concentrations
[32].
Covariates
Information on education level (illiterate, primary, sec-
ondary or higher education), smoking status (non-smokers,
former smokers or current smokers) and presence of
chronic disease (including among others stroke and
hypertension) was collected using questionnaires. The
Voorrips questionnaire, designed to assess physical activity
level in elderly people, was used to obtain information on
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habitual physical activity [33]. Subjects were divided into 3
groups according to sex-specific tertiles: low, moderate or
high physical activity level. Dietary intake was assessed by
trained dietitians using the dietary history method. The
method consisted of a 3-day estimated record and a fre-
quency checklist of foods, based on the meal pattern of the
country and with the previous month as a reference period.
Portion sizes were checked by weighing quantities of food
and household measures. Intakes of nutrients and food
groups were calculated in each country using local food
composition tables. Food consumption data were arranged
into food groups following the EUROCODE classification
system [34].
Statistical analyses
Population characteristics are reported as mean with
standard deviation (SD) or percentages. Medians with
interquartile range were used to report skewed variables.
Chi-squared tests for categorical variables and one-way
analysis of variance for continuous variables were per-
formed to compare baseline characteristics over tertiles of
25(OH)D. Multiple regression analyses were performed to
study the associations between 25(OH)D and fasting
plasma glucose (FPG), fasting plasma insulin (FPI) and
HOMA-IR as markers of insulin resistance. FPG, FPI and
HOMA-IR were not normally distributed and therefore
logarithmically transformed. b’s are presented as % with
95 % CI per 1 nmol/L increase in 25(OH)D (Table 3). As
both mental health variables followed a Poisson distribu-
tion, rate ratios (RRs) for 25(OH)D with global cognitive
performance [35] and depression were calculated using
multiple Poisson regression with the number of erroneous
answers as outcome for global cognitive functioning and
the number of depressive symptoms as an outcome for
depression. Participants were categorized according to
tertiles of 25(OH)D, using the lowest tertile as the refer-
ence category. In addition, a P- for trend across tertiles of
25(OH)D was calculated. All analyses were adjusted for
age, sex (model 1), BMI, education, smoking, alcohol
consumption, physical activity, study centre (model 2) and
intake of calcium (model 3). To control for total energy
intake, calcium intake was adjusted for total energy intake
by using the regression residual method. The analyses were
performed using the statistical package SAS, version 9.1
(SAS Institute Inc., Cary, NC, USA).
Results
General characteristics of the study population are pre-
sented in Tables 1 and 2. The mean ± SD 25(OH)D level
of the total population was 37.8 ± 20.6 and ranged from 6
to 141 nmol/L. Serum 25(OH)D levels below 50 nmol/L
and below 75 nmol/L were observed in 79 % and 94 % of
the participants, respectively. Participants living in the
southern part of Europe were more likely to have a sub-
optimal 25(OH)D level than those living in northern
countries (data not shown). Those with the highest
25(OH)D levels were more likely to be men (P = 0.02),
older (P \ 0.0001) and higher educated (P = 0.001).
Moreover, BMI (P = 0.07), FPG (P = 0.04), FPI (P =
0.06) and HOMA-IR (P = 0.05) were lower, and physical
activity levels (P = 0.0005) and total cholesterol concen-
trations (P = 0.001) were higher among those with the
highest serum vitamin D levels. Thirty-two per cent of the
SENECA study: 2,586 participants (1988/1989)
glucose and insulin, n=1,554 
(1988/1989)
25(OH)D, n=860 
(1988/1989)
GDS, n=482 and MMSE, n=443 
(1993)
25(OH)D, glucose, insulin and 
MMSE, n=94
25(OH)D, glucose, insulin and 
GDS, n=98
25(OH)D with insulin and glucose, 
n=593
25(OH)D with MMSE, n=116
25(OH)D with GDS, n=118
Fig. 1 Flow diagram
describing the population used
in the analyses
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participants had FPG levels, which exceeded 6.0 mmol/L.
Mean MMSE and median GDS scores of the population
were 27.4 ± 2.0 and 2.0 (IQR 3.0), respectively. As the
maximum score on the MMSE and GDS is, respectively,
30 and 15, these results indicate a low prevalence of mild
cognitive impairment or depressive symptoms. When
compared with the total sample, persons in the mental
health subsample were somewhat younger, had a lower
prevalence of chronic disease and moreover parameters of
glucose metabolism were slightly lower.
Table 3 presents the decline in FPG, FPI and HOMA-IR
in percentages per 1 nmol/L increase in 25(OH)D. An
inverse association was observed between 25(OH)D and
FPG (-0.1 %, 95 % CI: -0.2, 0.0), indicating a 1 %
decrease in FPG per 10 nmol/L increase in 25(OH)D;
however, after adjustment for demographic factors, life-
style factors and calcium intake, this association was not
statistically significant (P = 0.07). Significant inverse
associations were also found for 25(OH)D with FPI and
HOMA-IR, but these were attenuated after adjustment for
covariates. Stratified analysis for calcium intake demon-
strated a stronger association for 25(OH)D with FPG for
those with a high calcium intake (-0.2 %, 95 % CI: -0.3,
0.0), compared to those with a low intake (0.0 %, 95 % CI:
-0.2, 0.1) (data not shown in table). The interaction term,
however, was not statistically significant, P = 0.38 (data
not shown in table).
Data on serum 25(OH)D levels and depression were
available of 118 participants (Table 4). Fully adjusted
models showed that compared to the reference group, those
Table 1 Characteristics of 593 elderly European men and women of the SENECA study per tertile of serum 25(OH)D
T1 (6–27 nmol/L) T2 (28–42 nmol/L) T3 (43–141 nmol/L) P value
N 204 196 193
25(OH)D (nmol/L) 19.2 ± 5.3 34.3 ± 4.1 61.0 ± 18.3 \0.0001
Men, n (%) 86 (42) 98 (50) 108 (56) 0.02
Age 74.9 ± 1.4 74.6 ± 1.5 74.2 ± 1.6 \0.0001
Body mass indexa 27.4 ± 4.4 26.8 ± 4.1 26.5 ± 3.4 0.07
Fasting plasma glucose (mmol/L) 6.2 ± 1.9 6.1 ± 1.6 5.8 ± 1.5 0.04
Fasting plasma insulin (pmol/L) 67.9 (46.8) 74.5 (61.3) 62.4 (43.4) 0.06
HOMA-IR 1.31 (0.91) 1.45 (1.17) 1.21 (0.88) 0.05
Chronic disease present, n (%)b 166 (81) 158 (81) 144 (75) 0.24
Total cholesterol (mmol/L) 6.2 ± 1.2 6.5 ± 1.3 6.7 ± 1.1 0.001
Hypertension, n (%) 49 (24) 42 (21) 30 (16) 0.23
Stroke, n (%) 5 (2) 13 (7) 11 (6) 0.10
Smoking status, n (%)
Non-smoking 122 (60) 106 (54) 100 (52) 0.16
Current smoker 39 (19) 33 (17) 31 (16)
Former smoker 43 (21) 57 (29) 62 (32)
Physical activity level, n (%)
Low 44 (22) 30 (15) 16 (8) 0.0005
Average 74 (36) 67 (34) 58 (30)
High 86 (42) 99 (51) 119 (62)
Educational level, n (%)
Primary education 122 (60) 110 (56) 102 (53) 0.001
Secondary education 48 (23) 64 (33) 54 (28)
Higher education 14 (7) 9 (4) 29 (15)
Illiterate 20 (10) 13 (7) 8 (4)
Calcium intake (mg/day)a 960 ± 433 998 ± 424 1,021 ± 358 0.33
Alcohol intake (g/day)a 0 (10) 2 (13) 1 (9) 0.17
Values are expressed as a mean ± SD, median with IQR or n (%). P value for v2 test for categorical variables and one-way analysis of variance
for continuous variables
a 12 missing values
b Presence of chronic disease was defined as hypertension, ischaemic heart disease, stroke, malignancy, arthritis/arthrosis, inflammatory bowel
disease, respiratory problems, chronic liver disease, osteoporosis, Parkinson, others
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in the middle or upper tertile of 25(OH)D had on average a
27 % (RR 0.73, 95 % CI: 0.51–1.04) and 24 % (RR 0.76,
95 % CI: 0.52–1.11) (P for trend: 0.16) lower depression
score, respectively. Additional adjustment for calcium
intake (RR upper tertile 0.82 and 95 % CI: 0.59–1.14),
FPG (RR upper tertile 0.88 and 95 % CI: 0.61–1.25)
(n = 83, data not shown in table) or the prevalence of
hypertension (RR upper tertile 0.82 and 95 % CI:
0.59–1.14, data not shown in table) did not alter the
direction of the results.
Among 116 participants of whom 25(OH)D concentra-
tions were known and the MMSE was completed
(Table 4), age- and sex-adjusted models did not show
significant associations for those in the middle or highest
vitamin D group, RR 1.19 (95 % CI: 0.86–1.63) and RR
0.76 (95 % CI: 0.54–1.08), respectively. Further adjust-
ment unexpectedly resulted in a statistically significant
higher number of erroneous answers for those with inter-
mediate vitamin D levels, RR 1.39 (95 % CI: 1.00–1.94).
No such association was however observed for those with
the highest vitamin D levels, RR 0.94 (95 % CI:
0.63–1.39). Associations did not substantially change when
FPG levels, hypertension or depression were included in
the model (RRs upper tertile 0.90 (95 % CI: 0.56–1.45),
1.03 (95 % CI: 0.69–1.55) and 0.89 (95 % CI: 0.58–1.35),
respectively, data not shown in table).
Discussion
In this cross-sectional population-based study among
European elderly, participants with higher serum 25(OH)D
concentrations tended to have less depressive symptoms.
The data does not support the hypothesis that higher serum
Table 2 Mental health characteristics of 135 elderly European men and women of the SENECA study per tertile of serum 25(OH)D
T1 (7–33 nmol/L) T2 (34–52 nmol/L) T3 (53–125 nmol/L) P value
N 50 43 42
Age 73.8 ± 1.8 73.7 ± 1.7 73.2 ± 1.6 0.06
MMSE scorea 27.3 ± 2.1 26.8 ± 2.1 27.9 ± 1.9 0.06
GDS scoreb 2.0 (3.0) 2.0 (2.5) 2.0 (2.0) 0.32
Fasting plasma glucose (mmol/L)c 5.7 ± 0.9 6.1 ± 2.1 5.7 ± 1.3 0.43
Fasting plasma insulin (pmol/L)c 63.8 (46.3) 64.8 (57.4) 48.6 (44.3) 0.84
HOMA-IRc 1.17 (0.88) 1.22 (1.01) 0.93 (0.89) 0.76
Chronic disease present, n (%)e 34 (77) 26 (68) 28 (67) 0.54
Calcium intake (mg/day)d 899 ± 352 934 ± 325 1,064 ± 360 0.07
a 19 missing values
b 17 missing values
c 21 missing values
d 11 missing values
e Presence of chronic disease was defined as hypertension, ischaemic heart disease, stroke, malignancy, arthritis/arthrosis, inflammatory bowel
disease, respiratory problems, chronic liver disease, osteoporosis, Parkinson, others
Table 3 Associations between 25(OH)D and markers of glucose metabolism of 593 men and women participating in the SENECA study,
presented as % with 95 % CI per 1 nmol/L increase in 25(OH)D
Fasting plasma glucose (mmol/L) Fasting plasma insulin (pmol/L) HOMA-IR
Crude -0.1 -0.2, 0e -0.4 -0.7, 0d -0.4 -0.7, 0
Model 1a -0.1 -0.2, 0e -0.3 -0.6, 0.1 -0.3 -0.9, 0.1
Model 2b -0.1 -0.2, 0 -0.1 -0.4, 0.3 -0.1 -0.5, 0.3
Model 3c -0.1 -0.2, 0 -0.1 -0.4, 0.3 -0.1 -0.5, 0.3
a Adjusted for age and sex
b Adjusted for age, sex, BMI, education (categorical), alcohol intake (categorical), smoking (categorical), physical activity (categorical) and
study centre (categorical)
c Adjusted for age, sex, BMI, education (categorical), alcohol intake (categorical), smoking (categorical), physical activity (categorical), study
centre (categorical) and calcium intake (continuous)
d P \ 0.05
e P B 0.01
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vitamin D levels are associated with a better cognitive
performance. Moreover, despite a modest inverse associa-
tion between 25(OH)D and fasting plasma glucose, the
hypothesized independent health benefits of 25(OH)D on
insulin resistance could not be confirmed in this study.
Before interpreting the results, several methodological
issues warrant further discussion. First of all, blood sam-
ples were collected during the winter season and therefore
reflect the lowest 25(OH)D concentrations throughout the
year. Secondly, serum 25(OH)D was measured only once
and may therefore not reflect long-term status. Further-
more, the debate on the most accurate method to determine
serum 25(OH)D levels is still ongoing [36], but the com-
petitive protein-binding (CPB) assay applied in this study
might not be the most optimal method. A previous study
comparing different serum 25(OH)D assays showed that
CPB assay was highly correlated with radioimmunoassay
(RIA) (r = 0.72) and high-performance liquid chroma-
tography (HPLC) (r = 0.69). Additionally, mean 25(OH)D
levels as measured with CPB assay appeared to be sys-
tematically higher compared to HPLC and RIA [37]. The
CPB assay used in our study may therefore have resulted in
an overestimation of the true 25(OH)D status. However,
since it concerns a systematic overestimation, it will not
have affected the strength or the direction of the observed
associations. A strength of this study is that 25(OH)D
samples were taken in ten countries all over Europe, col-
lected during the same month and analysed in one single
laboratory. Therefore, seasonal variation or inter-laboratory
variation cannot have affected the results. Another strength
of the SENECA database is that it includes extensive
information on lifestyle and dietary factors including
physical activity level and calcium intake, reducing the
possibility of confounding significantly. Residual con-
founding by potential covariates as PTH, however, cannot
be ruled out.
Descriptive analyses showed lower 25(OH)D levels
among those with a higher BMI, lower physical activity
level and persons at older age. It may be suggested that in
our population, those with a higher physical activity level
performed part of their exercises outdoors, which may have
resulted in higher 25(OH)D levels. The decrease in
25(OH)D with age may be explained by the fact that the
production of vitamin D in the skin decreases while ageing
[38]. Lower 25(OH)D levels among persons with a higher
BMI have also been observed in previous studies and have
been suggested to be the consequence of the storage of
25(OH)D in fat tissue and thus not being bioavailable in
serum [39].
Among individuals in the SENECA study, FPG
decreased with 1 % when 25(OH)D increased with
10 nmol/L; however, this was not statistically significant
after adjustment for multiple factors. No association was
observed between 25(OH)D with FPI or HOMA-IR. Bio-
logical evidence that vitamin D may affect markers of
glucose metabolism and the development of diabetes is
increasing [4, 40]. Previous published cross-sectional
studies show however inconsistent results [41–46]. Among
142 Dutch men aged 70–88 years, 25(OH)D was inversely
associated with the area under the curve for both glucose
and insulin, which remained significant after adjustment for
BMI, skinfold thickness, alcohol, smoking and physical
activity [41]. High levels of 25(OH)D were furthermore
positively associated with insulin sensitivity and inversely
correlated with b-cell function in a population of 126
young adults who underwent a hyperglycaemic clamp
Table 4 Associations between 25(OH)D and mental health of 118 men and women participating in the SENECA study
T1 (0–34 nmol/L) T2 (34–52 nmol/L) T3 (52–125 nmol/L) P for trend
GDS (depression)
Crude model, n = 118 1.0 0.78 (0.53–1.14) 0.76 (0.50–1.15) 0.05
Model 1a, n = 118 1.0 0.80 (0.55–1.16) 0.76 (0.49–1.17) 0.05
Model 2b, n = 103 1.0 0.73 (0.51–1.04) 0.76 (0.52–1.11) 0.16
Model 3c, n = 103 1.0 0.74 (0.53–1.06) 0.82 (0.59–1.14) 0.41
MMSE (global cognitive functioning)
Crude model, n = 116 1.0 1.19 (0.87–1.64) 0.78 (0.54–1.12) 0.04
Model 1a, n = 116 1.0 1.19 (0.86–1.63) 0.76 (0.54–1.08) 0.04
Model 2b, n = 103 1.0 1.42 (1.02–1.97)d 0.92 (0.63–1.36) 0.39
Model 3c, n = 103 1.0 1.39 (1.00–1.94)d 0.94 (0.63–1.39) 0.51
a Adjusted for age and sex
b Adjusted for age, sex, BMI, education (categorical), smoking (categorical), physical activity (categorical), alcohol intake (categorical) and
study centre (categorical)
c Adjusted for age, sex, BMI, education (categorical), smoking (categorical), physical activity (categorical), alcohol intake (categorical), study
centre (categorical) and calcium intake (continuous)
d P B 0.05
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experiment [44]. Moreover, inverse associations with
measures of insulin resistance were observed among par-
ticipants of the Framingham Heart Study [43] and
NHANES III [46]. The LIPGENE study [45] and the
Women’s Health Initiative [42] were not able to confirm
previous evidence for a possible link between 25(OH)D
and glucose metabolism. A recently published systematic
review and meta-analyses with data of 5 prospective cohort
studies showed that persons with 25(OH)D levels higher
than 62.5 nmol/L had a 43 % lower risk of developing type
2 diabetes when compared to those with levels below
35 nmol/L [15]. Mitri and colleagues (2011) also summa-
rized the results of RCTs in this field and concluded that
these trials do not yet provide definite evidence for a
beneficial role of vitamin D supplementation on glycemic
outcomes [15].
Despite a small sample size, this cross-sectional study
showed a modest non-significant association between
25(OH)D and depression. Up to now, only very few pop-
ulation-based studies examined the possible link between
25(OH)D and depressive symptoms, showing contradictory
results. For instance, 1-year follow-up of 7,358 middle-
aged and elderly Americans diagnosed with a cardiovas-
cular event, without previous depressive episode, showed
that patients with a 25(OH)D level[125 nmol/L were less
often depressed compared to persons with 25(OH)D levels
B37.5 nmol/L, HR 2.70 (1.35–5.40) [7]. Physical activity,
socio-economic status or BMI were however not included
as covariates. At 6 year of follow-up, women participating
in the InCHANTI Study with the lowest 25(OH)D levels
reported significantly more depressive symptoms, com-
pared to those in the highest tertile. It has to be mentioned
that a relatively large number (42 %) of the women par-
ticipating in this study reported to have a depressed mood
[8]. Furthermore, significantly lower 25(OH)D levels were
also observed among 1,282 Dutch middle-aged and elderly
with minor and major depressive symptoms, compared to
those without depressive symptoms [6]. No clear beneficial
role for vitamin D in depression was observed in popula-
tion-based studies among Chinese elderly and Japanese
municipal officials aged 21–67 years [25–27]. In one of
these studies among Chinese elderly, a significant associ-
ation between 25(OH)D and depression was observed at
baseline, but not after 4 years of follow-up. The incidence
rate of depression at 4 years of follow-up was 4 % and in
addition only 6 % of the men had 25(OH)D levels below
50 nmol/L, which may perhaps partially explain the lack of
the association observed after 4 years [25]. Inconsistencies
between studies may also be the result of differences in the
ascertainment and prevalence of depression, lack of
adjustment for covariates and differences in geographical
location. As persons with depressive symptoms may be less
likely to go outside, associations between serum vitamin D
and depression observed in cross-sectional studies may also
be the result of reverse causation. By performing RCTs, the
possibility of reverse causation can be eliminated. How-
ever, up to now, only very few trials studied the effect of
vitamin D supplementation on mood or depression, show-
ing conflicting findings [47–51].
While there was evidence of an inverse association
between 25(OH)D and the number of depressive symp-
toms, no association was observed between 25(OH)D and
the number of erroneous answers on the MMSE. Results
of several small studies reviewed by Annweiler and col-
leagues [5], and more recent and larger community-based
cohort studies show either no or a positive association
between vitamin D and global cognitive performance [16,
18, 21, 23–25]. In 1,766 persons C65 years, low vitamin
D levels appeared to increase the probability of experi-
encing cognitive impairment, particularly in men [21].
Results of the EPIDOS study point towards the same
direction in a population of elderly women (OR 1.99,
95 % CI: 1.13–3.52, P = 0.02), even after adjustment for
iPTH, serum calcium and depression [16]. Prospective
data of the InCHANTI Study revealed that non-demented
vitamin D deficient (\25 mmol/L) men and women were
64 % more likely to experience cognitive decline, com-
pared to those in the sufficient group (C75 mmol/l) [23].
The MrOS study [24], NAME study [18] and Os study
[25] did not observe an association between serum vitamin
D and global cognitive function. Recently, the first RCT
on vitamin D supplementation and cognitive functioning
was published, which did not show an effect of a 6-week
treatment with 125 lg cholecalciferol on working mem-
ory, response inhibition or cognitive flexibility in young
adults [47]. Despite the fact that we could adjust for a
large number of important confounders, our sample size
may not have been large enough to detect an association.
Moreover, data on global cognitive functioning were
collected 4 years following the baseline measurements,
which may also have affected the association studied.
Although serum vitamin D levels have been shown to
decrease with age [52], 2-year follow-up data of 80 fragile
elderly, with a mean age of 82.1 years, showed however
only a 6 nmol/L decrease in 25(OH)D [53]. Therefore, we
expect that only a subtle decrease in 25(OH)D levels may
have occurred during the period until the mental health
indicators were measured.
In conclusion, this study showed a tendency towards an
inverse association of 25(OH)D with FPG and depression
but not with FPI, HOMA-IR and not with global cognitive
performance. As the overall evidence for a role of vitamin
D in glucose metabolism and mental health is still incon-
clusive, more prospective epidemiological studies, meta-
analysis, randomized controlled trials and mechanistic
studies are warranted.
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